PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:

Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van โt Veer, PhD; Elma Meershoek-Klein Kranenbarg, MS; Marjolijn Duijm-de Carpentier, BS; Cornelis J. H. Van de Velde, MD; Miranda Kleijn, PhD; Christa Dreezen, MS; Andrea R. Menicucci, PhD; William Audeh, MD; Gerrit-Jan Liefers, MD, PhD Title: Selection of Patients With Read More
Incorporating Immunotherapy in the Management of Early-Stage Estrogen Receptor-Positive Breast Cancer
Publication: ESMO Open - Volume 9 - Issue 11 - 2024 1 Authors: G. Nader-Marta, A. G. Waks, S. M. Tolaney, E. L. Mayer Title: Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer Abstract Immune checkpoint inhibitors (ICI) have been incorporated into standard treatment regimens for Read More
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Title: Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Authors: Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk, Rolando Garcia-Milian, Denise M Wolf, Laura A Huppert, Rita Nanda, Gillian L Hirst, Erin F Read More
70โGene signatureโguided adjuvant systemic treatment adjustments in earlyโstage ER+ breast cancer patients: 7โyear followโup study
Title: 70โGene signatureโguided adjuvant systemic treatment adjustments in earlyโstage ER+ breast cancer patients: 7โyear followโup of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, Josรฉ H. Volders, Annette W. G. van der Velden, Read More
Identification of Racial Disparities (ESMO 2024)
Publication: ESMO 2024 Authors: Sonya Reid, M.D., Jennifer G. Whisenant, Ph.D.; Jennifer Wei, M.D., Ph.D., Harshini Ramaswamy, M.Sc., Nicole Stivers, Ph.D., Andrea Menicucci, Ph.D., William Audeh, M.D., Tuya Pal, M.D. Title: Identification of racial disparities across MammaPrintยฎ and BluePrintยฎ subtypes in HR+HER2- breast cancer Background: Black women in the Read More
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreNSABP B-42 Trial shows MammaPrint Low Risk is Predictive of EET – JCO Publication
Journal of Clinical Oncology, July 24, 2024 Authors: Rastogi, et al.
Read More